Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Labcorp Corporation of America Holdings, Inc Clear all
Completed No phase listed Observational

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

NCT06008457
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
Interventions
Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
2 Years to 89 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 8, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 8, 2026, 10:16 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

NCT04938635
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID, Placebo
Drug
Lead sponsor
Vifor (International) Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 8, 2026, 10:16 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

NCT05740280
View directory record Official record
Conditions
Healthy Volunteers
Interventions
iCP-NI, Placebo
Drug
Lead sponsor
Cellivery Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 8, 2026, 10:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Variation in Urine Electrolytes, pH and Specific Gravity Throughout the Day

NCT03645785
View directory record Official record
Conditions
Healthy
Interventions
Normal fluid intake without true lemon, Double fluid intake plus 3 bottles of water with True Lemon
Dietary Supplement
Lead sponsor
Adam Howe, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 8, 2026, 10:16 AM EDT
Completed No phase listed Observational

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

NCT05697198
View directory record Official record
Conditions
Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Interventions
OmniSeq Test
Diagnostic Test
Lead sponsor
Labcorp Corporation of America Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Fort Payne, Alabama • Orange City, Florida • Stuart, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 8, 2026, 10:16 AM EDT
Not listed Phase 1Phase 2 Interventional

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

NCT05498389
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, EGFR Mutation-Related Tumors
Interventions
EMB-01, Osimertinib
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 8, 2026, 10:16 AM EDT
Not listed Phase 1Phase 2 Interventional

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

NCT05176665
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
Interventions
EMB-01
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 8, 2026, 10:16 AM EDT
Recruiting No phase listed Observational

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

NCT07543757
View directory record Official record
Conditions
Prostate Cancer Detection
Interventions
Proclarix
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
San Diego, California • Meridian, Idaho • Bowling Green, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 8, 2026, 10:16 AM EDT
Terminated No phase listed Observational

Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation

NCT00581178
View directory record Official record
Conditions
Kidney Stones
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 8, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

NCT05511558
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-Fosgonimeton
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 8, 2026, 10:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

NCT05222165
View directory record Official record
Conditions
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions
Infigratinib
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 8, 2026, 10:16 AM EDT
Completed No phase listed Observational

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

NCT04566653
View directory record Official record
Conditions
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Interventions
Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Temple Terrace, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 8, 2026, 10:16 AM EDT